Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)
Status:
Completed
Trial end date:
2017-04-30
Target enrollment:
Participant gender:
Summary
To evaluate the effect of Dornase alfa on preterm and late preterm neonates with ventilator
associated pulmonary infections. Dornase alfa has been effective in the treatment of
pulmonary infections in patients with cystic fibrosis by aiding mucus clearance. The bacteria
causing pulmonary infections in cystic fibrosis patients is similar to those infecting
preterm infants. The investigators expect that dornase alfa therapy will improve recovery
from ventilator associated pulmonary infections in preterm infants.